Publicaciones en colaboración con investigadores/as de Universidad de Salamanca (40)

2024

  1. Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events

    Journal of Hepatology

  2. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

  3. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  2. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  3. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

2022

  1. Impact of alternative splicing variants on liver cancer biology

    Cancers, Vol. 14, Núm. 1

2021

  1. Association of foxo3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: A systematic review with meta-analysis

    Cancers, Vol. 13, Núm. 21

  2. Impact of alternative splicing on mechanisms of resistance to anticancer drugs

    Biochemical Pharmacology, Vol. 193

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression

    Hepatology, Vol. 72, Núm. 3, pp. 949-964

  3. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

  4. Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma

    Cells, Vol. 9, Núm. 2

  5. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters

    Biochemical Pharmacology, Vol. 171

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps

    Archives of Toxicology, Vol. 93, Núm. 3, pp. 623-634

  3. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  4. Mechanisms of anticancer drug resistance in hepatoblastoma

    Cancers, Vol. 11, Núm. 3

  5. Models for understanding resistance to chemotherapy in liver cancer

    Cancers, Vol. 11, Núm. 11

  6. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

    Liver International, Vol. 39, Núm. S1, pp. 43-62